Ilmarinen Mutual Pension Insurance Co Decreases Stake in Bristol Myers Squibb Company $BMY

Key Points

• Ilmarinen Mutual Pension Insurance Co cut its Bristol Myers Squibb stake by 10.4% in the fourth quarter, selling 36,700 shares and leaving it with 315,800 shares worth about $17.0 million.
• Bristol Myers Squibb reported better-than-expected quarterly results, with EPS of $1.58 versus $1.42 expected and revenue of $11.49 billion versus $10.93 billion expected. Revenue rose 2.6% year over year.
• The company continues to offer a 4.4% dividend yield on its $0.63 quarterly payout, while analysts currently rate the stock a consensus Hold with an average price target of $61.31.

Ilmarinen Mutual Pension Insurance Co lowered its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 10.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 315,800 shares of the biopharmaceutical company's stock after selling 36,700 shares during the quarter. Ilmarinen Mutual Pension Insurance Co's holdings in Bristol Myers Squibb were worth $17,034,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of BMY. Brighton Jones LLC lifted its position in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after buying an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock valued at $346,000 after acquiring an additional 2,786 shares during the period. United Bank increased its holdings in shares of Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock valued at $1,164,000 after acquiring an additional 3,277 shares during the period. Marshall Wace LLP acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $221,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $405,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $56.93 on Friday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The stock has a market capitalization of $116.26 billion, a P/E ratio of 15.99, a P/E/G ratio of 0.16 and a beta of 0.26. The company's fifty day moving average is $58.36 and its two-hundred day moving average is $56.25. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analysts' expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. Bristol Myers Squibb's revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb's payout ratio is currently 70.79%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BMY shares. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 target price on the stock. HSBC lifted their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a "hold" rating in a report on Tuesday, March 17th. Cantor Fitzgerald lifted their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a report on Wednesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Guggenheim reaffirmed a "buy" rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.